Lacrisert Articles
Austrianova to explore possibilities in diabetes
4 September 2006
Cost issues compel pharma to make drug development more financially-viable: F&S report
19 September 2005
Ireland's Alltracel seeks AIM listing
6 June 2001
DAIICHI PHARMACEUTICAL DEVELOPMENT
10 May 1993
B-MS ACQUIRES LICENSE
22 March 1993
Showing 1-7 of 7 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
